Welcome to our dedicated page for Iradimed SEC filings (Ticker: IRMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The iRadimed Corporation (IRMD) SEC filings page on Stock Titan aggregates the company’s official disclosures filed with the U.S. Securities and Exchange Commission. These documents provide structured detail on financial performance, governance, and material events related to iRadimed’s business of MRI-compatible medical devices, including non-magnetic IV infusion pump systems and MRI-compatible patient vital signs monitoring systems.
Among the key filings are Form 8-K current reports, which iRadimed uses to announce events such as quarterly financial results, changes in its Board of Directors, and outcomes of stockholder meetings. For example, Form 8-K filings have reported record quarterly revenue, the use of non-GAAP financial measures like non-GAAP net income and free cash flow, the completion of a new facility in Orlando, Florida, and the retirement and appointment of directors. Other 8-Ks furnish press releases that detail FDA 510(k) clearance for the MRidium 3870 IV Infusion Pump System and summarize voting results from the Annual Meeting of Stockholders.
Filings also disclose listing information for iRadimed’s common stock, including its trading symbol IRMD and its listing on the NASDAQ Global Market, with one filing referencing the NASDAQ Capital Market. Governance-related sections describe board committee assignments, independence determinations, and advisory votes on executive compensation. These documents collectively give insight into how the company is overseen and how major decisions are communicated to investors.
On Stock Titan, iRadimed’s SEC filings are paired with AI-powered summaries that explain the contents of lengthy documents in plain language. Users can quickly see the main points of quarterly earnings announcements, board changes, and stockholder votes without reading every page. Real-time updates from EDGAR ensure that new 8-Ks and other filings appear promptly, while AI-generated highlights help readers identify sections related to financial condition, risk factors, and corporate actions. For those researching IRMD’s regulatory history and ongoing obligations, this page offers a focused view of its official SEC reporting.
Form 144 filed for IRADIMED CORP (IRMD) reports a proposed sale of 100,000 shares of common stock through Roth Capital Partners on 09/17/2025 with an aggregate market value of $7,076,000. The filing identifies the securities as held by the Phillip Susi 2008 Dynasty Trust, acquired on 01/01/1992, and indicates 2,362,500 shares were acquired by that trust on that date. The total shares outstanding reported in the filing are 12,720,002. The filer certifies there are no undisclosed material adverse facts known to the seller and states there were no sales in the past three months by the selling person.
Joe E. Kiani, a director of iRadimed Corporation (IRMD), filed an initial Form 3 reporting the event dated 09/02/2025. The filing states that the reporting person does not beneficially own any securities of the issuer as of the filing. The signature on the form is dated 09/10/2025.
IRadimed Corporation (IRMD) amended its annual report describing its business of MRI-compatible medical devices and related risks, operations, and governance. The company highlights a proprietary MRI-safe IV infusion pump system cleared to operate inside MRI rooms up to the 10,000 gauss-line, features such as optional DERS, wireless remote display, an add-on channel, and Masimo SET-based SpO2 monitoring. Management discloses dependence on a limited number of products, a single Florida manufacturing facility, and key-person concentration with Chairman/CEO Roger Susi exerting significant influence. The filing lists material risks including regulatory approvals and FDA inspections, supply-chain and supplier concentration risks, product liability and intellectual property exposure, cybersecurity controls, and competitive pressures. Recent capital projects include purchase of 26 acres in Orlando and ongoing construction of an expanded facility; the company expects to vacate its Winter Springs leased site once the new facility is operational. The filing also details share counts, stock-based compensation reserves and deferred revenue test procedures.
iRadimed Corporation reported the appointment of Mr. Kiani to its board of directors and furnished a related press release as Exhibit 99.1. The board has determined that Mr. Kiani is "financially literate" under Nasdaq rules. The filing states there are no arrangements or understandings between Mr. Kiani and any other person regarding his appointment and that he has no transactions requiring disclosure under Item 404(a) of Regulation S-K. The notice appears limited to the director appointment and required disclosures; it does not provide biographical details, committee assignments, equity holdings, or other background information about Mr. Kiani.
iRadimed CFO John Glenn reported significant insider transactions on June 20, 2025. The transactions involved:
- Acquisition of 5,796 shares through the vesting of Restricted Stock Units (RSUs)
- Disposition of 1,412 shares at $58.24 per share through share withholding for tax purposes
- Net beneficial ownership change to 13,151 shares held directly
The RSUs were originally granted on June 20, 2022, under iRadimed's 2014 Equity Incentive Plan, vesting in four equal annual installments starting June 20, 2023. This transaction represents the third vesting installment. The Form 4 was filed within the required reporting timeframe, demonstrating compliance with SEC disclosure requirements.
iRadimed held its Annual Meeting of Stockholders on June 19, 2025, where shareholders voted on three key proposals. All proposals passed successfully.
The voting results included:
- Board Elections: Five directors were elected with varying levels of support: - Hilda Scharen-Guivel received highest support (10.8M votes) - Anthony Vuoto (10.8M votes) - Monty Allen (9.5M votes) - Roger Susi (8.9M votes) - James Hawkins (8.4M votes)
- Auditor Ratification: RSM US LLP was confirmed as independent auditor with overwhelming support (11.8M votes in favor)
- Executive Compensation: Advisory resolution on executive compensation approved with strong support (10.8M votes in favor, 287K against)
The meeting demonstrated strong shareholder participation with approximately 11.8M total votes cast, including 709,490 broker non-votes on certain matters.
FAQ
What is the current stock price of Iradimed (IRMD)?
What is the market cap of Iradimed (IRMD)?
